Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Poziotinib |
Synonyms | |
Therapy Description |
Poziotinib (HM781-36B) is a pan-ErbB inhibitor that inhibits EGFR, ERBB2 (HER2) and ERBB4 (HER4), thereby reducing proliferation of tumor cells that overexpress these receptors (PMID: 21306821, PMID: 31588020). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Poziotinib | HM781-36B|NOV120101 | EGFR Inhibitor (Pan) 62 HER inhibitor (Pan) 6 | Poziotinib (HM781-36B) is a pan-ErbB inhibitor that inhibits EGFR, ERBB2 (HER2) and ERBB4 (HER4), thereby reducing proliferation of tumor cells that overexpress these receptors (PMID: 21306821, PMID: 31588020). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03804515 | Phase I | Poziotinib | A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib | Terminated | USA | 0 |
NCT03318939 | Phase II | Poziotinib | Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | Terminated | USA | NLD | ITA | ISR | FRA | ESP | CAN | BEL | 0 |
NCT05378763 | Phase III | Poziotinib Docetaxel | A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations (PINNACLE) | Suspended | USA | 0 |
NCT03744715 | Phase II | Poziotinib | A Study to Allow Continued Treatment of Patients Who Have Participated in a Spectrum-Sponsored Poziotinib Study | Terminated | USA | 0 |
NCT03066206 | Phase II | Poziotinib | Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC | Active, not recruiting | USA | 0 |
NCT02659514 | Phase II | Poziotinib | Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer | Completed | USA | 0 |
NCT04172597 | Phase II | Poziotinib | A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies | Terminated | USA | 0 |